Clinical trial
Cilengitide in Treating Patients With Prostate Cancer
NCT00121238 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00121238 |
|---|---|
| Title | Cilengitide in Treating Patients With Prostate Cancer |
| Official title | Phase II Evaluation of EMD 121974 (NSC 707544, Cilengitide) in Patients With Non-Metastatic Androgen Independent Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer |
| Intervention type | Drug |
| Interventions | cilengitide |
| Enrollment | 16 |
| Start date | Jan 1, 2005 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2015 |
| First posted | Jul 21, 2005 |
| Last update posted | Apr 28, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: